Indore Online Journal

Otitis Media Market Size in the 7MM is expected to grow by 2032 | DelveInsight

 Breaking News
  • No posts were found

Otitis Media Market Size in the 7MM is expected to grow by 2032 | DelveInsight

April 16
17:35 2024
Otitis Media Market Size in the 7MM is expected to grow by 2032 | DelveInsight

DelveInsight’s “Otitis Media Market Insights, Epidemiology, and Market Forecast—2032” report delivers an in-depth understanding of the Otitis Media, historical and forecasted epidemiology as well as the Otitis Media market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan.

 

Key Takeaways from the Otitis Media Market Research Report

  • The increase in Otitis Media Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
  • As per DelveInsight analysis, the Otitis Media market is anticipated to witness growth at a considerable CAGR.
  • The leading Otitis Media Companies working in the market include Pfizer, Inc., Sanofi S.A, Novartis AG, GlaxoSmithKline, Eli Lilly and Company, Merck, Vaxcyte, Clarametyx Biosciences, Blue Water Biotech, Abbott, Otonomy, Inc., Alcon Research, Arbor Pharmaceuticals, Inc., Currax Pharmaceuticals, Daiichi Sankyo, Inc., Johnson & Johnson, Arbor Pharmaceuticals, Replidyne, Salvat, Otic Therapy, and others
  • Promising Otitis Media Pipeline Therapies in the various stages of development include V114, VAX-24, CMTX-301, S. pneumoniae vaccine, cefdinir, Augmentin (ES)-600, OTO-201 (ciprofloxacin), Moxidex otic, Telithromycin (HMR3647), AR01, Antipyrine and Benzocaine, ofloxacin otic solution, levofloxacin, Faropenem Medoxomil, Zmax, benzocaine, DF289, Benzocaine, and others.
  • March 2024: Anabio R&D- LiveSpo Navax® and placebo 0.9% NaCl physiological saline are indistinguishable regarding taste and smell. The color and turbidity of LiveSpo Navax® suspension is unrecognizable to investigators except the PI and analyzer, nurses, patient’s parents, and patients due to opaque plastic container.
  • February 2024: Merck Sharp & Dohme LLC announced a study of phase 3 clinical trials for V114. The primary objective is to evaluate V114 in the prevention of vaccine-type acute otitis media (VT-AOM) and the safety of V114 with respect to the proportion of participants with serious adverse events (SAEs) through completion of the study. The primary hypothesis is that V114 is superior to no V114 in preventing VT-AOM as assessed by the incidence of VT-AOM.
  • January 2024: AventaMed DAC- The objective of this study is to evaluate the safety and performance of the Solo+ Tympanostomy Tube Device for the placement of tympanostomy tubes (grommets) in paediatric patients undergoing a tympanostomy procedure.
  • January 2024: PhotoniCare Inc.- The objective of this study is to clinically develop and evaluate a machine learning approach to improve the performance and data interpretation of the PhotoniCare OtoSight Middle Ear Scope in pediatric patients presenting at the primary care office for suspected ear infections. In this observational study, results of OtoSight imaging will not affect patient standard of care.

 

Discover which therapies are expected to grab the Otitis Media Market Share @ Otitis Media Market Outlook

 

Otitis Media Overview 

Otitis media is a polymicrobial disease, an ear infection in the middle ear. Fluid buildup behind the ear drum leads to middle ear infections. This fluid in the middle ear, is called an effusion, and can cause temporary hearing loss. Otitis media is a multifactorial disease with an extensive causal basis, including demographic, social, environmental, immunological and microbial risk factors. It predominantly occurs as coincident to viral upper respiratory tract infections or bacterial infections.

 

Otitis Media Epidemiology Insights

The epidemiology section of Otitis Media offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

  • Total Otitis Media Incident Cases
  • Otitis Media Etiology-specific Cases
  • Otitis Media Age-specific Cases
  • Otitis Media Treated cases

 

Download the report to understand which factors are driving Otitis Media Epidemiology trends @ Otitis Media Epidemiological Insights

 

Otitis Media Drugs Market

The Otitis Media Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Otitis Media signaling in Otitis Media are likely to uncover new therapeutic targets and further expand treatment options for patients.

 

Otitis Media Treatment Market Landscape

Antibiotics are the mainstay of treatment of uncomplicated otitis media in adults, and initial antibiotic choice is determined by knowledge of the most common causative pathogens. The preferred antibacterial drug for the patient with AOM must be active against S. pneumoniae, nontypeable H. influenzae, and M. catarrhalis. The treatment of otitis media is not always appropriate, and the long-term overuse of antibiotics reduces the effectiveness of treatment and places children at risk for drug-resistant infections. Further vaccination is recommended due to lack of effective therapies. There is a need for effective therapies. The Otitis Media treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Otitis Media has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

 

To know more about Otitis Media treatment guidelines, visit @ Otitis Media Treatment Market Landscape

 

Otitis Media Market Outlook

The report’s outlook on the Otitis Media market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Otitis Media therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Otitis Media drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Otitis Media market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

 

Otitis Media Drugs Uptake

  • V114 being developed by Merck, consists of pneumococcal polysaccharides from 15 serotypes conjugated to a CRM197 carrier protein and includes serotypes 22F and 33F, which are commonly associated with invasive pneumococcal disease worldwide and are not contained in the pneumococcal conjugate vaccine currently licensed for use in adults. Currently, the drug is in Phase III stage of clinical trial evaluation for the treatment of Acute Otitis Media, and has been approved in Europe.
  • VAX-24 being developed by Vaxcyte, is a clinical-stage 24-valent pneumococcal conjugate vaccine (PCV) designed to improve upon existing vaccines by covering the serotypes responsible for most of the remaining pneumococcal disease currently in circulation. It is being developed for the treatment of otitis media. Vaxcyte aims to efficiently create and deliver high-fidelity, broad-spectrumvaccines, such as VAX-24, by using modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform. Vaxcyte is deploying this approach with VAX-24 in order to add more pneumococcal strains without compromising the overall immune response. The company plans for VAX-24 (adults), end-of-Phase II meeting with FDA in 2H 2023, with Phase III pivotal immunogenicity data in 2025. While for infants Phase II study is enrolling subjects with topline data from the primary threedose immunization series by 2025.
  • CMTX-301 being developed by Clarametyx’ is using anti-DNABII technology through a vaccination approach in at-risk populations. This approach prevents the development of bacterial biofilm, enabling the body’s normal immune responses to more effectively destroy bacterial pathogens. The first targeted indication is otitis media. Preventing formation of biofilm and eliminating bacteria at potential infection sites will reduce the incidence of otitis media, and thus reduce antibiotic usage. The drug is under preclinical development

 

Major Otitis Media Companies

Several Otitis Media Companies working in the market include Pfizer, Inc., Sanofi S.A, Novartis AG, GlaxoSmithKline, Eli Lilly and Company, Merck, Vaxcyte, Clarametyx Biosciences, Blue Water Biotech, Abbott, Otonomy, Inc., Alcon Research, Arbor Pharmaceuticals, Inc., Currax Pharmaceuticals, Daiichi Sankyo, Inc., Johnson & Johnson, Arbor Pharmaceuticals, Replidyne, Salvat, Otic Therapy, and others

 

Learn more about the FDA-approved drugs for Otitis Media @ Drugs for Otitis Media Treatment

 

Scope of the Otitis Media Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Otitis Media Companies- Pfizer, Inc., Sanofi S.A, Novartis AG, GlaxoSmithKline, Eli Lilly and Company, Merck, Vaxcyte, Clarametyx Biosciences, Blue Water Biotech, Abbott, Otonomy, Inc., Alcon Research, Arbor Pharmaceuticals, Inc., Currax Pharmaceuticals, Daiichi Sankyo, Inc., Johnson & Johnson, Arbor Pharmaceuticals, Replidyne, Salvat, Otic Therapy, and others
  • Otitis Media Pipeline Therapies- V114, VAX-24, CMTX-301, S. pneumoniae vaccine, cefdinir, Augmentin (ES)-600, OTO-201 (ciprofloxacin), Moxidex otic, Telithromycin (HMR3647), AR01, Antipyrine and Benzocaine, ofloxacin otic solution, levofloxacin, Faropenem Medoxomil, Zmax, benzocaine, DF289, Benzocaine, and others.
  • Otitis Media Market Dynamics: Otitis Media Market Drivers and Barriers
  • Otitis Media Market Access and Reimbursement, Unmet Needs, KOL’s Views, and Analyst’s Views

 

Discover more about Otitis Media Drugs in development @ Otitis Media Clinical Trials Assessment

 

Table of Content

1. Key Insights

2. Executive Summary of Otitis Media

3. Competitive Intelligence Analysis for Otitis Media

4. Otitis Media: Market Overview at a Glance

5. Otitis Media: Disease Background and Overview

6. Patient Journey

7. Otitis Media Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Otitis Media Unmet Needs

10. Key Endpoints of Otitis Media Treatment

11. Otitis Media Marketed Products

12. Otitis Media Emerging Therapies

13. Otitis Media: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Otitis Media

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories